Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ducentis BioTherapeutics
United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Ducentis BioTherapeutics developed DS-234, a preclinical fusion protein agonist of the CD200 receptor aimed at restoring immune tolerance. DS-234 demonstrated favorable preclinical results across potency, efficacy, and pharmacokinetics versus comparable CD200R antibodies. No clinical data is yet available; the program was acquired specifically for its preclinical promise in atopic dermatitis and autoimmune disease.[1][5][7][8]
- Therapeutic areas
- ImmunologyDermatology
- Modalities
- Fusion proteinBiologic
- Industry
- Biotech
02
Partnerships
LifeArc
Beyond the preview
Go deeper on Ducentis BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ducentis BioTherapeutics.